Risk of serious cardiac events in older adults using antipsychotic agents

American Journal Geriatric Pharmacotherapy

Volumn 9, Issue 2, 2011, Pages 120-132

  Mehta, Sandhya ^a   Chen, Hua ^a   Johnson, Michael ^a   Aparasu, Rajender R ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

antipsychotics; atypical; cardiac; cohort; elderly; typical

Indexed keywords

ACETOPHENAZINE; AMITRIPTYLINE PLUS PERPHENAZINE; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; CYCLOOXYGENASE 2 INHIBITOR; FLUPHENAZINE; HALOPERIDOL; HORMONE; LOXAPINE; MESORIDAZINE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PIMOZIDE; PROCHLORPERAZINE; PROMAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; THIOTHEXENE; TRIFLUOPERAZINE; TRIFLUPROMAZINE; UNCLASSIFIED DRUG; ZIPRASIDONE;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; FEMALE; GROUPS BY AGE; HEART ARREST; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL; THROMBOEMBOLISM; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 79955931977     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2011.03.004     Document Type: Article

References (66)

1. Osborn DPJ, Levy G, Nazareth I, et al. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. Arch Gen Psychiatry. 2007;64:242-249. (Pubitemid 46220782)
2. Curkendall SM, Mo J, Glasser DB, et al. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatry. 2004;65:715-20.
3. Osby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res. 2000;45:21-28.
4. Colton CW, Manderschied RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis. 2006;3:A42.
5. Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58:844-850. (Pubitemid 32979302)
6. Michelsen JW, Meyer JM. Cardiovascular effects of antipsychotics. Expert Rev Neurother. 2007;7:829-839. (Pubitemid 47037723)
7. Buckley NA, Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Saf. 2000;23:215-228.
8. Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr Pharm Des. 2004;10:2463-2475. (Pubitemid 38997427)
9. Mackin P. Cardiac side effects of psychiatric drugs. Hum Psychopharmacol. 2008;23(Suppl 1):3-14. (Pubitemid 351166608)
10. Haddad PM, Andersen IM. Antipsychotic-related QTc-prolongation, Torsade de pointes and sudden death. Drugs. 2002;62:1649-1671.
11. Vieweg WV. New generation antipsychotic drugs and QTc interval prolongation. Prim Care Companion J Clin Psychiatry. 2003;5:205-215.
12. US FDA. Information for Healthcare Professionals: Conventional Antipsychotics. June 2008. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm. Accessed February 12, 2009.
13. Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res. 2004;71:195-212. (Pubitemid 39330499)
14. Jano E, Chen H, Johnson ML, Aparasu RR. Antipsychotic utilization and expenditure trends among elderly persons. Psychiatr Serv. 2007;58:1400. (Pubitemid 350207259)
15. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223. (Pubitemid 41345943)
16. Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology. 2002;28(Suppl 1):9-26.
17. Mittelmark MB, Psaty BM, Rautaharju PM, et al. Prevalence of cardiovascular diseases among older adults. The Cardiovascular Health Study. Am J Epidemiol. 1993;137: 311-317. (Pubitemid 23090465)
18. Liperoti R, Gambassi G, Lapane KL, et al. Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest. Arch Intern Med. 2005;165:696-701. (Pubitemid 40393155)
19. Liperoti R, Pedone C, Lapane KL, et al. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotics agents. Arch Intern Med. 2005;165:2677-2682. (Pubitemid 41785068)
20. Nakagawa S, Olsen PML, Mortensen PB, Sorensen HT. Antipsychotics and risk of first-time hospitalization for myocardial infarction: a population-based case-control study. J Int Med. 2006;260:451-458. (Pubitemid 44571133)
21. Hennessy S, Bilker WB, Knauss JS, et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ. 2002;325:1070.
22. Straus SM, Bleumink GS, Dieleman JP, et al. Antipsychotic and the risk of sudden cardiac death. Arch Intern Med. 2004;164:1293-1297. (Pubitemid 38828879)
23. Lacut K, Gal GL, Couturaud F, et al. Association between antipsychotic drugs, antidepressant drugs and venous thromboembolism: results from the EDITH case-control study. Fundam Clin Pharmacol. 2007;21:643-650. (Pubitemid 350151244)
24. Ray WA, Meredith S, Thapa PB, et al. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry. 2001;58:1161-1167. (Pubitemid 33121508)
25. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360:225-235.
26. Enger C, Weatherby L, Reynolds RF, et al. Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis. 2004;192:19-27. (Pubitemid 38101693)
27. Ray JG, Mamdani MM, Yeo EL. Antipsychotic and antidepressant drug use in the elderly and the risk of venous thromboembolism. Thromb Haemost. 2002;88:205-209. (Pubitemid 34873699)
28. Trifirò G, Spina E, Gambassi G. Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have similar safety profile? Pharmacol Res. 2009;59:1-12.
29. Wang PS, Schneeweiss S, Setoguchi S, et al. Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications. J Clin Psychopharmacol. 2007;27:707-710. (Pubitemid 351339462)
30. Setoguchi S, Wang S, Brookhart A, et al. Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications. J Am Geriartr Soc. 2008;56:1644-1650.
31. IMS Data Assets. PharMetrics Integrated Database. http://www.imshealth. com/portal/site/imshealth/menuitem.a46c6d4df3db4b3d88f611019418c22a/?vgnextoid= 6d7660b6f5aa0210VgnVCM100000ed152ca2RCRD&vgnextchannel= bc42650204850210VgnVCM100000ed152ca2RCRD&vgnextfmt=default. Accessed October 24, 2009.
32. Valuck RJ, Libby AM, Sills MR, et al. Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study. CNS Drugs. 2004;18:1119-1132. (Pubitemid 40007494)
33. Gill SS, Bronskill SE, Normand SLT, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146:775-786. (Pubitemid 351650498)
34. Schneeweiss S, Setoguchi S, Brookhart, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176:627-632. (Pubitemid 46426056)
35. World Health Organization. ICD-9: International Statistical Classification of Diseases and Relation Health Problems. 9th Rev. Geneva: World Health Organization, 1978.
36. Elixhauser A, Steiner CA, Whittington CA, et al. Clinical Classifications for Health Policy Research: Hospital Inpatient Statistics, 1995. Healthcare Cost and Utilization Project, HCUP-3 Research Note. Rockville, MD: Agency for Healthcare Research and Quality; 2000. AHCPR Pub. No. 98-0049.
37. Grobee DE. Confounding and indication for treatment in evaluation of drug treatment for hypertension. BMJ. 1997;315:1151-1154.
38. Glynn RJ, Schneeweiss S, Stürmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol. 2006;98:253-259.
39. D'Agostino R Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265-2281.
40. Baser O. Too much ado about propensity score models? Comparing methods of propensity score matching. Value Health. 2006;9:377-385. (Pubitemid 44511151)
41. Brookhart MA, Schneeweiss S, Rothman KJ, et al. Variable selection for propensity score models. Am J Epidemiol. 2006;163:1149-1156. (Pubitemid 43987579)
42. Aparasu RR, Jano E, Johnson ML, Chen H. Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients. Am Geriatr Pharmacother. 2008;6:198-204.
43. Parson LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. http://www2.sas.com/proceedings/sugi26/p214-26.pdf. Accessed March 30, 2009.
44. Feng WW, Jun Y, Plaines D, et al. A method/macro based on propensity score and mahalanobis distance to reduce bias in treatment comparison in observational study. http://www.lexjansen.com/pharmasug/2006/ publichealthresearch/pr05.pdf. Accessed on April 7, 2009.
45. Alexander MT, Kufera JA. Butting heads on matched cohort analysis using SAS Software. http://www.nesug.org/proceedings/nesug07/sa/sa01.pdf. Accessed May 1, 2009.
46. Austin PC. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med. 2008;27:2037-2049.
47. Austin PC. Type I error rates, coverage of confidence intervals, and variance estimation in propensity-score matched analysis. Int J Biostatist. 2009;5:article 13.
48. Gottlieb S. Warnings issued over COX 2 inhibitors in US and UK. BMJ. 2005;330:9.
49. Jones SC. Relative thromboembolic risks associated with COX-2 inhibitors. Ann Pharmacother. 2005;39:1249-1259. (Pubitemid 40943178)
50. Tanne JH. FDA places "black box" warning on antidiabetes drugs. BMJ 2007;334:1237.
51. Stephenson J. FDA orders estrogen safety warnings: agency offers guidance for HRT use. JAMA. 2003;289:537-538. (Pubitemid 37428620)
52. Leslie RS. Calculating medication compliance, adherence, and persistence in administrative pharmacy claims database. http://www.wuss.org/proceedings08/ 08WUSS%20Proceedings/papers/anl/anl09.pdf. Accessed April 12, 2009.
53. Dehejia RH, Wahba S. Propensity score-matching for nonexperimental causal studies. Rev Econ Stat. 2002;84:151-161.
54. Shader RI, Greenblatt DJ. Potassium, antipsychotic agents, arrhythmias, and sudden death. J Clin Psychopharmacol. 1998;18:427-428. (Pubitemid 28555323)
55. Drici MD, Priori S. Cardiovascular risks of atypical antipsychotic drug treatment. Pharmacoepidemiology and Drug Safety 2007;16:882-890. (Pubitemid 47322588)
56. Reilly JG, Ayis SA, Ferrier IN, et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000;355:1048-1052. (Pubitemid 30162807)
57. Taylor DM. Antipsychotics and QT prolongation. Acta Psychiatr Scand 2003;107:85-95. (Pubitemid 36164475)
58. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001;158:1774-1782. (Pubitemid 33054769)
59. Modai I, Hirschmann S, Rava A. Sudden death in patients receiving clozapine treatment: a preliminary investigation. J Clin Psychopharmacol 2000;20:325-327. (Pubitemid 30318361)
60. Canoso RT, De Oliveira RM, Nixon RA. Neuroleptic-associated autoantibodies. A prevalence study. Biol Psychiatry. 1999;27:863-870.
61. Davis S, Kern HB, Asokan R. Antiphospholipid antibodies associated with clozapine treatment. Am J Hematol. 1994;46:166-167. (Pubitemid 24181645)
62. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: II. Cardiac and analgesic drugs. J Am Geriatr Soc 1999;47:40-50. (Pubitemid 29044265)
63. Lohr KN. Emerging methods in comparative effectiveness and safety: symposium overview and summary. Med Care. 2007;45:S5-S8.
64. Swenson RJ, Doucette S, Fergusson D. Adverse cardiovascular events in antidepressant trial involving high risk patients: A systematic review of randomized trials. Can J Psychiatry 2006;51:923-929. (Pubitemid 46354056)
65. Taylor D. Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety. Acta Psychiatr Scand. 2008;118:434-442.
66. Simon JA, Hsia J, Cauley JA, et al. for the HERS Research Group. Postmenopausal hormone therapy and risk of stroke - The Heart and Estrogen-progestin Replacement Study (HERS). Circulation. 2001;103:638-642. (Pubitemid 32144190)